SCHEMBL900252

SCHEMBL900252

CCCC=CS(=O)(=O)N1CCN(c2cc(C)nc3ccccc23)CC1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 4/20 0.62
LMNA P02545 3/20 0.62
MAPK1 P28482 3/20 0.62
USP2 O75604 2/20 0.62
HSD17B10 Q99714 2/20 0.62
PKM P14618 1/20 0.62
SMN1; SMN2 Q16637 6/20 0.57
NPSR1 Q6W5P4 3/20 0.57
TSHR P16473 1/20 0.57
KMT2A Q03164 6/20 0.56
MEN1 O00255 5/20 0.56
NCF1 P14598 6/20 0.53
ADRB2 P07550 1/20 0.51
ADRB1 P08588 1/20 0.51
MAPT P10636 3/20 0.46
KDM4E B2RXH2 2/20 0.46
RECQL P46063 1/20 0.46
PSMD14 O00487 1/20 0.44
APAF1 O14727 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL900251 1.00 HTT (0.62) HTTLMNAMAPK1USP2HSD17B10
SCHEMBL900149 0.79 HTT (0.77) HTTLMNAMAPK1USP2HSD17B10
SCHEMBL15153027 0.74 MEN1 (0.70) HTTLMNAMAPK1USP2HSD17B10
SCHEMBL10271990 0.74 MEN1 (0.70) HTTLMNAMAPK1USP2HSD17B10
SCHEMBL8229816 0.74 NCF1 (0.76) HTTLMNAMAPK1USP2HSD17B10
SCHEMBL23373387 0.74 NCF1 (0.69) HTTLMNAMAPK1USP2HSD17B10
SCHEMBL15152938 0.74 MEN1 (0.78) HTTLMNAMAPK1USP2HSD17B10
SCHEMBL15152940 0.74 MEN1 (0.78) HTTLMNAMAPK1USP2HSD17B10
SCHEMBL5065450 0.73 NCF1 (0.88) HTTLMNAMAPK1USP2HSD17B10
SCHEMBL900221 0.73 HTT (0.60) HTTLMNAMAPK1USP2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2621923-B1 N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES INTERVET INT BV (NL) 2017-03-29 EP disclosed
US-8883791-B2 N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases INTERVET INC. (US) 2014-11-11 US disclosed
US-20130203768-A1 N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES INTERVET INC. 2013-08-08 US disclosed
EP-2621923-A1 N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES Intervet International B.V. (NL) 2013-08-07 EP disclosed
WO-2012041872-A1 N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES INTERVET INTERNATIONAL B.V. (NL) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203768-A1 N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES PIGO, HNMT, PIGS HTT 190/4885LMNA 981/4885MAPK1 4625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.